Northwestern University, Lurie Comprehensive Cancer Center

Chicago, Illinois 60611

0 studies enrolling now · 3 studies all time

What they study most

Biliary Tract Cancer, Bone Marrow Disease, Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations, Essential Thrombocytosis, Hematological Disease, Leukemia, Leukemia, Myelocytic, Acute, Myelodysplastic Syndrome (MDS)

Studies at this site

• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies — Completed
• Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) — Stopped early
• A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation — Completed